From the first launch to ongoing market access operational execution, IntegriChain solves some of the most complex and pressing challenges associated with drug commercialization. We deliver pharma’s only comprehensive data, consulting, and business process platform for market access departments, providing the strategy, data, applications, and infrastructure for therapy commercialization.
Solutions overview
IntegriChain delivers the pharmaceutical industry’s largest and only data and business process platform for therapy commercialization and access. Manufacturers rely on our analytics, applications, and managed services to power their operations and harness the value of their channel, patient and payer data.
View all products
IntegriChain provides a complete set of professional services for commercialization and market access execution–from life science strategy and operational consulting to implementation, integration, migrations, and analytics.
Services overview
We help all stakeholders in the pharmaceutical industry drive access with our relentless focus on unifying all of the critical business functions for therapy commercialization and access – contracts & pricing, gross-to-net, channel, and patient services – to unlock strategic payer, provider, pharmacy and patient access insights.
Learn more about our company
Learn more about joining our growing IntegriChain team of data scientists, market access experts, analysts, and consulting professionals – our culture, our purpose, our teams in the US and Pune. Check out our careers or keep in touch for future opportunities.
Careers overview
August 12, 2021
Philadelphia, PA, August 12, 2021 – IntegriChain, delivering Life Sciences’ only comprehensive data and business process platform for market access, today announced that it has been named to the Philadelphia Business Journal’s Soaring 76 list of top high-growth companies. A virtual awards event will be held September 23 at 11:00 am EST. Tickets are available at www.pbj.com/events.
“We have experienced tremendous growth over the last few years, and I am especially proud of our team in 2020 and into this current year as they successfully worked 100% remotely to ensure our Life Sciences customers could continue to get their life-saving and life-changing therapies into the hands of patients,” said IntegriChain CEO Kevin Leininger. “We thank the Philadelphia Business Journal for this honor, and we are proud to be headquartered in this great city and grow an outstanding team of data and analytics professionals serving Life Sciences.”
About IntegriChain IntegriChain is Life Sciences’ data and application backbone for patient access and therapy commercialization. More than 250 manufacturers rely on IntegriChain’s ICyte Platform to orchestrate commercial and government payer contracting, patient services, and distribution channels. ICyte is the first and only platform that unites the financial, operational, and commercial data sets required to support therapy access in the era of specialty and precision medicine. With ICyte, Life Sciences innovators are digitalizing labor-intensive processes – freeing up their best talent to identify and resolve coverage and availability hurdles and to manage pricing and forecasting complexity. IntegriChain is backed by Accel-KKR, a leading Silicon Valley technology private equity firm. The company is headquartered in Philadelphia, PA, with offices in Ambler, PA; Raleigh, NC, and Pune, India. For more information, visit www.integrichain.com, or follow us on Twitter @IntegriChain and LinkedIn.
Contact Jennifer Guinan, Sage Strategic Marketing, 610.410.8111, Jennifer@sagestrat.com
Save the date!
Webinars & Resources
See List
